4Kscore Test
Opko Health, Inc. · Decision date Jul 25, 2025
What did the FDA approve?
FDA records P190022/S003 as a supplement to PMA P190022, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Jul 25, 2025.
FDA approval order statement
Approval for the addition of the DRE Unavailable variant as part of the 4KScore Test system
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Immunology
- Decision date
- Jul 25, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P190022/S003
- Regulatory pathway
- PMA supplement
- Applicant
- Opko Health, Inc.
- Product code
- QRF
- Decision code
- APPR
- Decision date
- Jul 25, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Multi-analyte test system with algorithmic analysis for detection of prostate cancer.
- Applicant
- Opko Health, Inc.
- Product code
- QRF
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P190022/S003 received
Application receipt date recorded by FDA.
P190022/S003 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P190022. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code QRF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
IsoPSA AssayP200048/S001 | Cleveland Diagnostics, Inc. | PMA supplement | Jul 28, 2026 | FDA |
IsoPSA AssayP200048 | Cleveland Diagnostics, Inc. | PMA approval | Nov 28, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Opko Health, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 4400 Biscayne Blvd., Miami, FL, 33137
Sources and methodology
- Original FDA record: P190022/S003
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
